Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Sales rose 10.5% year-on-year, fueled by high demand for its radiopharmaceutical products, including PYLARIFY ... stock benefiting from the rise of AI, available to you FREE via this link.

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD ...